The longevity biotech expands BGE-102 into diabetic macular edema, betting that aging biology drives vision loss.
Vision loss is rarely framed as a longevity issue. Yet for millions of people aging with diabetes, it becomes one of the most tangible reminders that chronic inflammation does not stay confined to one organ. California-based biotech BioAge Labs now wants to change how that story is told.
The clinical-stage biotechnology company announced that it is expanding development of its lead drug candidate, BGE-102, into ophthalmology, with plans to initiate a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME) in mid-2026 [1]. The move extends BioAge’s core thesis – that targeting the biology of aging can unlock new treatment pathways across multiple diseases – into the retina.
For investors and longevity watchers, the announcement reflects a growing view that age-driven inflammation is a common thread linking cardiovascular disease, metabolic disorders, neurodegeneration and now vision loss.
DME is one of the most common causes of vision impairment among people with diabetes. Persistently high blood sugar damages the small blood vessels in the retina, leading to fluid leakage and vision distortion. While the condition is associated with diabetes, its progression is deeply tied to chronic inflammation, an underlying feature of aging itself.
Current treatments focus on managing the damage after it has already begun. Patients often receive regular injections directly into the eye, sometimes monthly, to control swelling and preserve vision. These therapies can be effective, but they are invasive, time-intensive and difficult to sustain over the years.
BioAge’s approach starts earlier in the inflammatory process. At the center of its strategy is NLRP3, a key driver of inflammation that becomes increasingly active with age and metabolic stress. When overactivated, it triggers a cascade of inflammatory signals that damage tissues throughout the body, including the retina.
BGE-102 is an oral NLRP3 inhibitor, designed to dampen inflammation at its source. What makes it particularly notable in ophthalmology is its potential to reach the retina via oral dosing, a property many drugs struggle to achieve.
If successful, this could significantly reduce treatment burden for patients who currently rely on frequent intravitreal injections.
According to Dr Kristen Fortney, CEO and co-founder of BioAge, the success of injectable IL-6 inhibitors in treating retinal diseases confirms that targeting the eye’s inflammatory cascade is an effective therapeutic strategy.
“NLRP3 sits at the apex of this cascade, and BGE-102 offers the potential to deliver broader anti-inflammatory benefit in an oral formulation, which could meaningfully reduce treatment burden for patients with serious, sight-threatening conditions who currently require frequent intravitreal injections,” she said.
That formulation matters not just clinically, but philosophically. An oral therapy reframes retinal disease as part of a systemic aging process, rather than a localized eye problem requiring localized intervention.
BioAge’s optimism does not come from theory alone; it comes from what the drug is already doing when put to the test.
In early laboratory studies designed to mimic diabetic eye disease, BGE-102 helped keep the retina’s tiny blood vessels intact. Instead of leaking fluid – the process that blurs vision in diabetic macular edema – the vessels largely held their shape and function. The drug appeared to protect the eye’s delicate plumbing before damage could spiral.
In studies examining aging in the retina more broadly, the results were equally telling. Blocking NLRP3 sharply reduced the buildup of lipofuscin, a toxic waste material that accumulates in eye cells over time and is closely linked to degenerative vision loss. Cutting that buildup by roughly 80% suggests the drug may be doing more than treating disease; it may be slowing an aging process that the eye struggles to clear on its own.
Human data from outside BioAge point in the same direction. In patients with macular edema, drugs that block IL-6, one of inflammation’s key messengers, have already led to lasting improvements in vision. These results have helped shift how doctors think about eye disease: inflammation is not just a side effect of damage, but a main cause of it.
BGE-102 fits into that evolving understanding. In an ongoing Phase 1 trial, the drug has been well tolerated and consistently reduced inflammatory signals in the body, including markers linked to cardiovascular and metabolic aging. These are the same signals that rise quietly over time, long before chronic disease becomes visible.
The next step is to see whether those anti-inflammatory effects extend into the eye itself. BioAge plans to begin a Phase 1b/2a clinical trial in patients with diabetic macular edema in mid-2026. The study will test BGE-102 on its own and alongside existing treatments, asking a straightforward but important question: can calming inflammation from the inside help protect vision, without relying solely on repeated eye injections?
Instead of jumping straight to the question everyone asks, “Does vision improve right away?” BioAge’s study is starting one step earlier.
The goal of the trial is to show that the drug is actually doing what it is meant to do inside the eye: calming the inflammation that slowly damages vision over time. Researchers will track changes in IL-6, a key inflammatory signal, directly within the eye to see whether BGE-102 is hitting its target where it matters most. From there, they will also look at practical signs patients care about, such as how clearly they can see and whether retinal swelling is decreasing.
The full picture will take time to emerge, with results expected in mid-2027, but that timeline reflects a careful attempt to understand how the drug works, not just if it works.
Notably, this eye study will run alongside BioAge’s ongoing cardiovascular trial. That is intentional. The company is betting on a simple yet increasingly accepted idea: inflammation is not an eye or heart problem. It is a whole-body process that shows up in different ways as we age. By studying the same drug across different organs at the same time, BioAge is testing whether one approach to aging biology can protect both how we see and how long we stay healthy.
BioAge has described BGE-102 as a potential “pipeline in a pill,” a single therapy aimed at NLRP3-driven inflammation across cardiovascular, central nervous system and ocular diseases. The expansion into eye disease brings that vision into sharper focus.
Preserving sight is not just about treating disease, but also about maintaining independence, mobility and quality of life as people age. If BioAge’s strategy holds, the retina may become one of the clearest examples yet that aging biology connects systems that have long been treated in isolation.
